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Abstract
Background: Cancer cells are known to over-express TRAF6 that is critical for both AKT and TAK1 activations. The
Really Interesting New Gene (RING) domain of TRAF6 is believed to be responsible for the E3 ligase activity, ZINC
fingers of TRAF6 provide critical support for the activity of the RING domain which is critical for both AKT and
TAK1 activations.
Methods: We employed computational docking program to identify small molecules that could effectively and
competitively bind with the RING domain of TRAF6, which is believed to be responsible for its E3 ligase activity. MTT
assay and flow cytometry were employed to analyze apoptosis of cancer cells. Signaling pathways were detected using
immunoprecipitation and western blotting, and immunofluorescence was pursued to assess the nature of binding of
cinchonine to TRAF6. We also performed animal experiments to test effect of cinchonine in vivo.
Results: Cinchonine, a naturally occurring Cinchona alkaloid identified from the docking study, could bind to TRAF6 in
HeLa and A549 cells and induce apoptosis of these cancer cells. We found that AKT ubiquitination and
phosphorylation as well as phosphorylation of TAK1 were decreased. These activities would lead to subsequent
suppression anti-apoptotic protein Bcl-2, while elevating pro-apoptotic protein Bax. Immunofluorescence staining
unambiguously demonstrated the binding of cinchonine specifically at the RING domain of TRAF6 in cells, thereby
validating the computational modeling. Animal experiments showed that cinchonine could suppress tumor growth in
mice without showing significant acute toxicity.
Conclusion: These investigations suggest that through competitive binding with the RING domain of TRAF6,
cinchonine could induce apoptosis via inhibiting AKT and TAK1 signaling pathways.
Keywords: Cinchonine, RING domain of TRAF6, AKT and TAK1 activations and phosphorylations, Immunofluorescence
staining, Ubiquitination
Background
Tumor necrosis factor (TNF) receptor associated factor 6
(TRAF6) like other TRAF members plays an indispensible
role in intracellular signal transductions of an array of re-
ceptor families such as T-cell/B-cell receptors and the TNF
receptor superfamily [1]. TRAF6 acts as a direct E3 ligase
for protein kinase B (AKT) and can also activate transform-
ing growth factor activated kinase 1 (TAK1) [2, 3]. More
significantly, it is also over-expressed in cancer cells [4–9].
Structurally, TRAF6 consists of four parts: the Really
Interesting New Gene (RING) domain, ZINC finger do-
main, a coiled-coil domain, and a C-terminal TRAF-C do-
main [10]. While the RING domain of TRAF6 is believed
to function as an E3 ubiquitin ligase, ZINC fingers of
TRAF6 provide critical support for the E3 ligase activity of
the RING domain [10–12]. Binding of the RING domain of
TRAF6 with ubiquitin-conjugating enzyme (Ubc13) and
ubiquitin-conjugating enzyme variant (UEV1A) is believed
to be crucial for the Lys-63 dependent activation of both
AKT [2] and TAK1 [3, 13, 14]. In recently studies, many re-
searchers have found that the level of AKT phosphoryla-
tions at Thr-308 and Ser-473 were significantly reduced in
TRAF6−/− mouse embryonic fibroblasts relative to TRAF6
+/+ [2]. In addition, it was reported that in mouse
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myoblasts, knockdown of TRAF6 appears to compromise
both TAK1 and AKT signaling pathways [15].
Both AKT and TAK1 are involved in growth factors,
metabolism, cell proliferation, survival, apoptosis and in-
flammatory responses [16–19]. Furthermore, AKT and
TAK1 can also accelerate the activation of downstream
nuclear factor κB (NF-κB) via phosphorylation of inhibi-
tor of NF-κB and then regulate apoptosis-related kinases
Bax/Bcl-2 [20–23], activator protein-1 and p38/mitogen-
activated protein kinase signaling pathways [24–27]. Pre-
viously in our own studies, we have uncovered that a
small molecule could bind at the RING domain of
TRAF6, leading to inhibition of the AKT activity [28].
Considering the strong association between TRAF6 and
activations of both AKT and TAK1 pathways, and their
implications on apoptosis and cell proliferation as well
as a possible therapeutic approach for treatment of can-
cer, we employed computational docking to identify
small molecules that can specifically bind with the RING
domain of TRAF6 and could compete with the binding
of its natural ligand Ubc13. We wish to report herein
our studies designed to explore the mechanism of which
a small molecule could block activations of AKT and
TAK1 and subsequently induce apoptosis of cancer cells
in vivo and in vitro.
Methods
Materials
HeLa and A549 cells were provided from Tianjin Inter-
national joint Academy of Biomedicine, Normal human
dermal fibroblast (NHDF) cells were provided from Pro-
fessor Jun Dai (Tianjin University, China). RPMI-1640,
DMEM, and FBS were purchased from Corning, Australia.
Cinchonine (Xiensi Biochemical Technology Co, Tianjin,
China) was dissolved in DMSO (Sigma-Aldrich). Phos-
phatase inhibitor and 3-(4,5-dimethyl-2-thiazoyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) were obtained
from Sigma, USA. HEPES was purchased from Solarbio
(Beijing, China). Apoptosis Detection Kit was purchased
from Becton-Dickinson, USA. Polyvinylidene Fluoride
(PVDF) membrane was purchased from Merk Millipore,
USA. In Situ Apoptosis Detection Kit, POD was pur-
chased from BOSTER (Wuhan, China). Protein A Sephar-
ose beads were brought from Pierce, USA. Balb/c-nude
mice and Kunming mice were purchased from Yi Sheng
Yuan Bio Logical Technology Co. Tianjin, China.
Antibodies used in this study include the following:
Ubiquitination antibody and rabbit anti-TRAF6 poly-
clonal antibody (Santa Cruz, USA); Rabbit polyclonal
antibody against total AKT, phosphorylation-AKT
(Thr-308), phosphorylation-AKT (Ser-473), total TAK1,
phosphorylation-TAK1 (Thr-184/Thr-187), Bax, and
Bcl-2 (Cell Signaling Technology, USA); Rabbit poly-
clonal antibody against TRAF6, ALEXA FLUOR 647
conjugated (Bioss Inc. USA); Rabbit anti β-actin poly-
clonal antibody, Goat anti-mouse, and goat anti-rabbit
IgG polyclonal antibody (Beijing Zhongshan Golden
Bridge Biotechnology Co., Ltd, China).
Cell culture
HeLa and A549 cells were cultured in RPMI-1640, while
NHDF cells were cultured in DMEM, both media were
supplemented with 10% FBS. All cells were incubated at
37 °C in a humidified atmosphere of 5% CO2.
Docking study
To first identify small molecules that could bind with
the RING domain of TRAF6, the three-dimensional
structure of the RING and ZINC finger domains (resi-
dues 50–159) of TRAF6 was obtained from the Protein
Data Bank database with an access code of 3HCT [29].
The structure was used in the docking experiments, and
the docking grid was placed over the RING domain
(residues 67–124) of TRAF6, which is believed to inter-
act with Ubc13. We carried out computational screening
of a small library of chemical compounds established by
Jkchemical Sigma, and Alfa Aesar that would include
1792 commercially available compounds. All structures
were built using a 2D/3D editor-sketcher and were mini-
mized to a local energy minimum using the CHARMm-
like force field. This library was docked into TRAF6
implemented by AutoDock4.10 software. Compounds
were filtered by the predicted binding free energy.
Further filtering rules were guided by chemical diversity,
rigidity, novelty and actual commercial availability.
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay
Cells were seeded into 96-well plate at density of 4.1 × 103
cells/well. Different concentrations (1, 5, 10, 50, 100, and
250 μM) of cinchonine were added to these wells. Cis-
platinum (16.7 μM) was used as a positive control. After
treating with cinchonine for 48, 72, and 96 h respectively,
the medium with different concentrations were removed
and cells were incubated with 20 μL MTT (5 mg/mL) for
4 h at 37 °C. The MTT solution was discarded and forma-
zan was dissolved in 150 μL DMSO. The absorbance of
each well was read using a Microplate reader (Shanghai
Kehua, China) at 490 nm [30]. Cell inhibition ratio was
calculated using the equation:
Cell inibition ratio %ð Þ ¼ 1‐ODtreated=ODcontrolð Þ
 100%
Half maximal inhibitory concentration (IC50) was cal-
culated by regression curve.
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Flow cytometry
Apoptosis of the cells were determined using the Annexin
V-FITC Apoptosis Detection Kit (Becton-Dickinson, Frank-
lin Lakes, NJ, USA) according to the manufacturer’s proto-
col [30]. In brief, cells were seeded into 60-mm plate and
the confluence was allowed to reach 50%–60%. After
which, according to MTT result, cinchonine was added
at concentrations of 100 μM, 150 μM, and 180 μM for
HeLa cells, and at concentrations of 150 μM, 180 μM,
and 220 μM for A549 cells at 37 °C for 48 h. Where-
after, cells were washed twice in cold PBS and then re-
suspended in 1× binging buffer, and 100 μL of the cell
suspension was transferred to a 5 mL culture tube, to
which 5 μL Annexin V-FITC and PI were added. The
mixture was incubated for 15 min at room temperature
in the dark. Results were immediately analyzed with a
FACScalibur flow cytometer and cell Quest Pro 5.1
(BD, Biosciences, Franklin Lakes, NJ, USA).
Immunoprecipitation
Cells were extracted with lysis buffer containing 50 mM
HEPES (pH 7.4), 150 mM NaCl, 1% NP-40. The lysate
was centrifuged at 12000 × g for 20 min at 4 °C, and the
supernatant containing total protein was harvested. Sub-
sequently, the total protein was exposed to anti-body
against AKT, which was immobilized on protein A beads
(Pierce). The resulting beads were incubated at 4 °C
overnight with gentle rotation, washed 3 times with lysis
buffer, and separated at 800 × g for 3 min. The desired
protein bands were visualized by Western blotting [31].
Western blot analysis
When the confluence reached 60%–70%, cells were
treated with 180 μM of cinchonine for different time.
After which, cells were treated with 20 μg/mL of lipo-
polysaccharide (LPS) for 3 h to induce activation of AKT
[31]. To induce activation of TAK1, 1 μg/mL of LPS was
used to treat the cells for 15 min [32]. The protein were
extracted with lysis buffer for 30 min on ice. Extracts
were centrifuged at 12000 × g for 20 min at 4 °C, and
the supernatants containing total protein were har-
vested. Each sample containing 50 μg protein was sepa-
rated by 10% SDS-PAGE and transferred to PVDF
membranes. The membrane was blocked in 5% non-fat
milk and incubated overnight at 4 °C with anti-bodies
against AKT (1:1000), phosphorylation-AKT (1:1000),
TAK1 (1:1000), phosphorylation-TAK1 (1:1000), ubiqui-
tin (1:1000), Bax (1:1000), Bcl-2 (1:1000), β-actin
(1:1000). Then the membranes were incubated at room
temperature for 1 h with their corresponding secondary
anti-bodies. The membranes were incubated with ECL
solution (CWBIO) and exposed to the film (FUJI, Japan).
The membranes were stripped and reblotted with β-
actin antibody to verify the equal loading of protein in
each lane. Image J software v.1.48u (National Institutes
of Health, Bethesda, MD, USA) was used to quantify the
intensity of protein bands.
Animal experiment
Animals were maintained in Institute of Radiation Medi-
cine Chinese Academy of Medical Science. All experi-
mental procedures using these mice were in accordance
with requirements and guidelines for treating experi-
mental animals approved by the National Institutes for
Food and Drug Control of China. All animal experi-
ments have been approved by The Ethics Committee on
animal experiments of Institute of Radiation Medicine
Chinese Academy of Medical Science (The approval
number is: (2016) 1–008). Balb/c-nude mice (four weeks
old and gender random) were first subcutaneously inoc-
ulated with cancer cells (5 × 106 cell/mL) to establish
transplanted mode of cervical cancer. After feeding the
nude mice for 3 weeks post implantation, the tumor vol-
ume was approximately 586.84 mm3 when intratumo-
rally injection commenced. The inoculated mice were
then divided into: experimental group-I to be intratumo-
rally injected with cinchonine (180 μM), experimental
group-II to be intratumorally injected with cinchonine
(360 μM), and control group (treated with medium).
The injection volume is 100 μL. Dosage of cinchonine
administrated to nude mice are 0.265 mg/Kg (180 μM)
and 0.530 mg/Kg (360 μM). The weight of nude mice
and the shortest and longest diameter of tumor were
measured with calipers with an interval of every other
day. Tumor volume (mm3) was calculated using the fol-
lowing standard formula: (the longest diameter) × (the
shortest diameter)2/2. The hyperplasia rate was calcu-
lated using: (“the volume of nude mice in day 2, 4, 6, 8,
10, 12, and 14” – “the volume of nude mice in day 2”)/
“the volume of nude mice in day 2”. There were 5 nude
mice in each group.
For the acute toxicity test, we used high-dosage intra-
venous injection, 500 μL of cinchonine (360 μM) with
injected into 5 male and 5 female Kunming mice, and
injected mice were observed for 14 d.
After treating with cinchonine for 14 d, paraffin sec-
tions were prepared from tumor tissues in the following
manner. The resulting paraffin sections were then
treated with an Apoptosis Detection kit (BOSTER, Wu-
han, China) according to the manufacturer's protocol
[33]. Briefly, paraffin sections were first incubated in
electric dry oven at 60 °C for 30 min before they were
placed into dimethyl benzene for 10 min and in fresh di-
methyl benzene for another 10 min. Subsequently, these
section were placed in a gradient of ethanol (5 min each
ethanol absolute, 95 and 75% ethanol). The proteinase K
was used to incubate them for 15 min at room
temperature before being washed with 0.01 M phosphate
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buffer saline solution. After these paraffin sections were
cultivated in terminal deoxynucleotidyl transferase
(TdT) buffer containing TdT and biotinylated DNA ura-
cil nucleoside triphosphate (dUTP) in TdT buffer, they
were incubated in a moist atmosphere at 37 °C for 2 h
and washed with TBS. Paraffin sections were then sealed
and cultivated with biotin in a wet atmosphere for
30 min at room temperature before being washed with
TBS. These sections were then incubated with Strept
Avidin-Biotin Complex (SABC) for 30 min in 37 °C and
washed with TBS. Lastly, paraffin sections were dyed
with diaminobenzidine (DAB) and counterstained with
Hematoxylin [34, 35], and the final toxicity analysis was
viewed under an optical microscope.
Immunofluorescence staining
The fluorescent probe, 7-(N,N-diethylamino) coumarin-
N-(4-bromobenzyl)-3-carboxamide, was conjugated to
the terminal olefin of cinchonine according to the fol-
lowing procedure. A mixture of 7-aminocoumarin
(150.0 mg, 0.35 mmol), cinchonine (51.4 mg, 0.18 mmol),
Pd(OAc)2 (2.00 mg, 8.7 μmol), PPh3 (4.80 mg, 18.0 μmol)
and Et3N (49.0 μL, 0.40 mmol) in anhydrous toluene
(2 mL) was capped under N2 atmosphere and heated at
110 °C for 24 h [36]. The resulting mixture was then
allowed to cool to room temperature, filtered through
CeliteTM, and washed with CHCl3. The filtrate was con-
centrated to dryness under reduced pressure, and the
resulting crude was purified using reversed-phase HPLC
to give the desired coumarin probe conjugated cinchon-
ine as yellow solid (17.0 mg, 15%).
Conditions for reversed-phase HPLC: Column, Cos-
mosil 5C18-AR300 (Nacalai Tesque, Inc.) 10 × 250 mm;
Mobile phase A, 0.1% TFA in H2O; B, 0.1% TFA in
CH3CN; Gradient elution, 0–4 min at 5% B, 4–34 min
at 5–95% B, 34–35 min at 95% B; Flow rate at 4 mL/
min; UV detection at 254 nm. 1H NMR (400 MHz,
CDCl3, 25 °C) δ 9.42 (t, J = 5.8 Hz, 1H, NH), 9.10 (d, J =
5.5 Hz, 1H), 8.70 (s, 1H), 8.40 (dd, J = 14.8, 8.6 Hz, 2H),
8.26 (d, J = 5.4 Hz, 1H), 7.99 (t, J = 7.7 Hz, 1H), 7.84 (t, J
= 7.7 Hz, 1H), 7.44 (d, J = 9.0 Hz, 1H), 7.34 (q, J =
9.5 Hz, 4H), 6.67 (dd, J = 9.0, 2.4 Hz, 1H), 6.59 (s, 1H),
6.53 (d, J = 15.8 Hz, 1H), 6.49 (d, J = 2.3 Hz, 1H), 6.33
(dd, J = 15.8, 7.7 Hz, 1H), 4.63 (d, J = 5.6 Hz, 2H), 4.40
(dd, J = 14.0, 7.1 Hz, 1H), 3.64–3.62 (m, 1H), 3.50–3.44
(m, 6H), 3.27 (q, J = 10.3 Hz, 1H), 2.79 (q, J = 8.2 Hz,
1H), 2.48 (t, J = 11.6 Hz, 1H), 2.14 (s, 1H), 2.02 (t, J =
8.4 Hz, 1H), 1.82 (q, J = 10.5 Hz, 1H), 1.24 (t, J = 7.1 Hz,
6H), 1.15–1.08 (m, 1H); ESI-HRMS m/z calcd for
C40H43N4O4 ([M +H]+) 643.3279, found 643.3282.
Cells grown on glass coverslips were incubated with
the fluorescent probe conjugated cinchonine for 1 h and
washed with ice-cold PBS. These cells were subsequently
fixed in 95% ethanol at room temperature for 30 min
and permeabilized with 0.2% Triton X-100. After being
blocked with 5% BSA in PBS, the cells were incubated
with Rabbit polyclonal antibody against TRAF6, ALEXA
FLUOR 647 conjugated (Bioss Inc. USA) for 2 h at 37 °C
[37]. Co-localization of modified cinchonine and TRAF6
was analyzed using fluorescence microscope. The fluor-
escence microscope used for immunofluorescence obser-
vation is Nikon eclipse 80i and the light is Nikon
INTENSILIGHT C-HGFI. The analysis software is NIS-
Elements. The image is a single layer. There was no
quantitative analysis of the co-localization.
Statistical analysis
Statistical analysis was performed with SPSS software and
the experimental values which between difference groups
were shown as the mean ± standard deviations. The statis-
tical significance of differences between the control and
treated groups were determined by Student’s t-test. Values
*p < 0.05 and **p < 0.01 are considered significant.
Results
Docking study and identification of cinchonine
We found cinchonine (Additional file 1: Figure S1), a
member of Cinchona alkaloid family, to be the most ef-
fective in binding to the RING domain of TRAF6. More
specifically, we found four possible areas for binding of
cinchonine to the RING domain. As shown in Fig. 1a,
after analyzing all four possible areas and comparing
their free energies, the most suitable binding mode for
cinchonine was determined, as it possesses the lowest
free energy (△G = −6.64 kcal/mol) of the four areas ana-
lyzed. In this binding mode, cinchonine appears to be
surrounded by amino acid residues of Asp-57, Glu-59,
Phe-60, Pro-63, Leu-64, Leu-74, and Ala-76, thereby re-
vealing also significant interactions with residues pre-
ceding (54–66) the RING domain (67–124). From the
expanded view as shown in Fig. 1b, there appear to be
hydrophobic interactions between the quinoline motif
of cinchonine and residues Phe-60, Leu-64, and Ala-76
of TRAF6. More significantly, we were able to verify
that the hydroxy group (−OH) of cinchonine forges a
key hydrogen bond with Asp-57, whereas the terminal
olefin of cinchonine does not interact with amino acid
residues of TRAF6. These structural observations pro-
vide a critical basis to pursue possible visualization of
such interaction in cells using a synthetically modified
cinchonine that would be substituted with a fluorescent
probe. In particular, we envisioned that if an appropri-
ate fluorophore could be conjugated at the terminal
olefin of cinchonine, it would remain outside the RING
domain and would not interfere the binding of cin-
chonine at this region.
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Inhibition of proliferation and induction of early
apoptosis in HeLa and A549 cells
Western blot assay showed that HeLa and A549 cells
established high expression levels of TRAF6 (Additional
file 1: Figure S2). In Figs. 2a and b, cinchonine inhibited
HeLa and A549 cells proliferation in a dose- and time-
dependent manner. In NHDF cells, using the same
concentration gradient, the inhibition ratio was signifi-
cantly lower than HeLa and A549 cells (Fig. 2c). With
the concentration of cinchonine being set at 180 μM, in-
hibition rates were 16.08, 22.07 and 24.95%, respectively,
for durations of 48, 72, and 96 h. We subsequently cal-
culated the half maximal (50%) inhibitory concentration
(IC50) value to be 180 μM through the computer-
Fig. 1 Docking result of cinchonine. a Binding of cinchonine (in cyan) with TRAF6. b The -OH group of cinchonine forges one hydrogen bond
(in pink) with residues Asp57 in TRAF6. c The binding of Ubc13 (in red) to TRAF6 (in blue). d The influence of cinchonine on the interaction between
TRAF6 and Ubc13
Fig. 2 Assessment of apoptosis by MTT assay. a The inhibition ratio of HeLa cells after treated with cinchonine for 48, 72, and 96 h. b and c
represented A549 and NHDF cells. Quantitative analysis of MTT represented as the mean ± SD of three independent experiments. *P < 0.05 and
**P < 0.01 when compared to untreated control
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estimated using the Pharmacologic Calculation Program
[38] and employed this concentration for the following
experiments.
After treatment with cinchonine for 48 h, the percent
of early apoptosis in control group was 4.53% ± 0.58.
The percent of apoptosis increased after being treated
with cinchonine. The fraction of early apoptosis in-
creased to 20.92% ± 1.21 when treated with 100 μM of
cinchonine and to 31.03% ± 1.87 with 150 μM of
cinchonine, while reaching 38.69% ± 1.62 with 180 μM
of cinchonine. As a positive control, Cis-platinum
(16.7 μM) showed 33.69% ± 4.10 of cells in the state of
early apoptosis (Fig. 3a). Therefore, we have demon-
strated here that cinchonine could induce early apop-
tosis in HeLa cells as well as in A549 cells (Fig. 3b).
Changes in AKT and TAK1 activations and levels of Bax/
Bcl-2
To understand the underlying molecular mechanism of
cinchonine induced apoptosis, ubiquitination and phos-
phorylation levels of AKT were analyzed in these two
cell lines. Immunoprecipitation showed that ubiquitina-
tion of AKT was down-regulated after being treated with
cinchonine for 1, 2 and 3 h (Fig. 4a). Furthermore, in
Fig. 4b, phosphorylations of AKT at Thr-308 and Ser-
473 were significantly impeded after treatment for 3 and
6 h. Phosphorylation levels of TAK1 at Thr-184 and
Thr-187 were analyzed and found reduced after expos-
ing these two cell lines to cinchonine (Fig. 5). Levels of
downstream apoptosis-related kinases protein Bax (pro-
apoptotic protein)) and Bcl-2 (anti-apoptotic protein)
were also examined. After cells were treated with cin-
chonine for 12, 24, 48, 72 and 96 h, the expression level
of Bax was increased significantly, while the level of Bcl-
2 decreased in a time-dependent manner in both cell
lines (Fig. 6). These results provide tangible evidence
that cinchonine could influence both AKT and TAK1
signaling pathways as well as their downstream proteins
like though its binding with TRAF6.
Possible tumor suppression in vivo
Tumor model in nude mice was successfully established,
and the tumorigenic rate was 100%. Uptake of food and
drink of nude mice was normal, and the mental state was
good. The tumor growth ratio of the experiment group-I
was 2.267 ± 0.467, while the experiment group-II was
1.324 ± 0.367, which is significantly lower than the control
group: 2.839 ± 0.583 (Fig. 7a). Weights of these mice were
approximately 18–22 g (Additional file 2: Table S1). Up-
take of food and drink of all Kunming mice was normal
and the mental state was good without any death or loss
of mobility after treatment with cinchonine for 14 d.
Comparing tumor tissues of nude mice from the three
groups, in situ TUNEL assay shows that experimental
groups have more nuclei being dyed than that of the
control group, thereby revealing the ability of cinchonine
to induce apoptosis of transplanted tumor cells in nude
mice (Fig. 7b).
Visualizing the binding of cinchonine with TRFA6 in HeLa
and A549 cells
Results of our docking study suggest that cinchonine
could effectively bind with TRAF6. To visualize such
interaction in cells, a coumarin-derived fluorescent probe
was conjugated specifically to the terminal olefin of
cinchonine via synthesis (Fig. 8a). Immunofluorescence
staining experiment using this modified cinchonine was
performed. Modified cinchonine (green fluorescence) and
TRAF6 (red fluorescence) were seen co-located in the
cytoplasm of HeLa and A549 cells (Fig. 8b), thereby sup-
porting the assessment that cinchonine could bind with
TRAF6 in cells.
Discussion
Wu et al. found that mutations of residues Asp-57
(D57K), Ile-72 (I72D), and Leu-74 (L74E or L74K) in
TRAF6 had significantly disrupted the TRAF6-Ubc13
interaction, the RING domain accounts for two of these
interactions: (a) Folding of residues Ile-72 and Leu-74
within the domain in a manner that they provide a
hydrophobic surface for Ubc13 to interact; and (b) a salt
bridge between Glu-69 of the RING domain and Arg-14
of Ubc13. The third key interaction involves residues
(residues 54–66), salt bridges are also observed in the X-
ray crystal structure between Asp-57 and Lys-10/Arg-6
of Ubc13 (Fig. 1c) [29]. Based on these assessments, our
docking studies would suggest that the presence of cin-
chonine, and in particular, the H-bond between its OH
group and the amino acid residue Asp-57, could effect-
ively prevent the salt-bridge formation between Asp-57
of TRAF6 and Lys-10/Arg-6 of Ubc13 (Fig. 1d). Conse-
quently, in the absence of this salt-bridge, the formation
of the TRAF6-Ubc13 complex would suffer. It is note-
worthy that the other salt bridge between Glu-69 of the
RING domain and Arg-14 of Ubc13 appears to remain
intact and unaffected by cinchonine (Fig. 1d). However,
without the assistance of a second salt bridge, it would
be difficult for Ubc13 to anchor firmly on the surface of
the RING domain of TRAF6, or at least, Ubc-13 would
be unable to complex properly with TRAF6 in a manner
sufficient for the ensuing activation of AKT and TAK1.
The main purpose of this work is to explore
whether the RING domain in TRFA6 could serve as a
viable anti-cancer therapeutic target. Because HeLa
and A549 cells have a high expression level of
TRAF6, we chose HeLa and A549 cells. The expres-
sion level of TRAF6 was shown in Supporting Information
(Additional file 1: Figure S2).
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Armed with these detailed computational analysis and
Western blotting results, we proceeded to pursue cell-
based assays using HeLa, A549, and NHDF (as controls)
cells, and found that cinchonine could inhibit prolifera-
tions of HeLa and A549 cells in a concentration- and
time-dependent manner. NHDF cells were used to test
cytotoxicity of cinchonine. The experiment showed that
cinchonine exhibits low cytotoxicity when used at low
concentrations. When the concentration of cinchonine
is set at 180 μM, the percent inhibition of NHDF cells
was also much lower than those of HeLa and A549 cells.
Karbwang et al. had reported pharmacokinetics of quin-
ine, quinidine, and cinchonine when given as a combin-
ation to patients with falciparum malaria. This
combination was given intravenously to patients every
8 h either at 400 mg or 600 mg dosage containing one
third of each component. The maximum amount of cin-
chonine used in each dosage would reach as high as
200 mg, which is 170 μM [39] and close to the IC50
value (180 μM) of cinchonine in our study. Therefore,
we chose 180 μM as an optimal concentration to con-
duct subsequent study of mechanism.
Fig. 3 Cinchonine induces the early apoptosis. The apoptosis level of HeLa (a) and A549 (b) cells were measured using the Annexin V-FITC and
Propidium iodide assay at 48 h after treatment with cinchonine. The results show cinchonine induces early apoptosis of cells in a concentration-
dependent manner. Cis-platinum (16.7 μM) was used as a positive control. Quantitative analysis of flow cytometry results represented as the
mean ± SD of three independent experiments. *P < 0.05 and **P < 0.01 when compared to control group
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Flow cytometry showed that cinchonine could induce
early apoptosis while does not cause cell death after
treating with cinchonine for 48 h.
AKT is known to be associated with many proteins
that contribute to cell survival [32]. Over-expression of
TRAF6 could increase phosphorylations of AKT at Thr-
308 and Ser-473 as well as AKT ubiquitination, leading
to enhanced AKT activity, and many reports suggest that
the expression level of ubiquitination-AKT is higher in
cancer cells than normal cells [40–42]. It is noteworthy
that Yang et al. had found that upon IGF-1 treatment,
endogenous AKT ubiquitination was less in TRAF6−/−
comparing to that in TRAF6+/+ in primary mouse em-
bryonic [2]. Reduction of ubiquitination-AKT in vivo
down-regulated the level of phosphorylation-AKT at
Thr-308 and Ser-473 [43, 44]. Lamothe et al. showed
that when down-regulating the expression of TRAF6,
levels of phosphorylations of AKT at Thr-308 and Ser-
Fig. 4 Cinchonine inhibited AKT activation. a Cells were exposed to cinchonine (180 μM) for 0, 3, 6, 12, and 24 h. Immunoprecipitation was performed
to determine the expression level of ubiquitination of AKT. Result shows that the ubiquitination-AKT was lower with the treatment of cinchonine. b
Cells were pre-treated with cinchonine for the indicated durations and Western blotting was carried out to show us that cinchonine down-regulated
the phosphorylation of AKT significantly at 3 and 6 h. The results shown are the mean ± SD of three independent experiments. *P < 0.05 and **P < 0.01
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473 were lowered [12]. Our results also revealed that
cinchonine led to reduced expression levels in both ubi-
quitination and phosphorylation of AKT, thereby imped-
ing the AKT activation (Figs. 4a and b).
TRAF6 is also known to facilitate phosphorylation of
TAK1 and its subsequent activities thereof. Yamashita et
al. reported that in TRAF6-deficient mouse embryonic
fibroblasts, TAK1 failed to be auto phosphorylated at
Thr-184 and Thr-187 and could not activate c-Jun N-
terminal kinase (JNK) [3, 27, 45]. Therefore, auto phos-
phorylation levels of TAK1 were analyzed in these two
cell lines and the observed reduction of TAK1 auto
phosphorylations is likely associated with the binding of
cinchonine to the RING domain of TRAF6.
We had demonstrated that cinchonine could reduce
proliferation and induce apoptosis in both HeLa and
A549 cells. There are reports documenting that phos-
phorylation of AKT and TAK1 can inactivate Bax, while
increasing the Bcl-2 activity [20–22, 27]. The Bcl-2 pro-
tein family contains pro-apoptotic member Bax and
anti-apoptotic member Bcl-2, which are considered to
be active effectors and regulators [46]. More specifically,
Fig. 5 Cinchonine inhibited phosphorylation of TAK1. Cells were treated with cinchonine (180 μM) for 0, 3, 6,12, and 24 h. Western blotting was
performed to determine the expression level of phosphorylation of TAK1. Result shows that cinchonine inhibited phosphorylation of TAK1. The
results shown are the mean ± SD of three independent experiments. *P < 0.05 and **P < 0.01
Fig. 6 Changes of the expression levels of Bax/Bcl-2. Cells were treated with cinchonine (180 μM) for the indicated durations. Western blotting was
subsequently performed to determine the expression of Bax/Bcl-2 in the cell lines. Result shows that the expression level of Bax was increased while
Bcl-2 was decreased. The data represent mean ± SD of three independent experiments. *P < 0.05 and **P < 0.01
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Bcl-2 regulates signal pathways that can ensure cell sur-
vival, while Bax is a negative regulator of Bcl-2 [47–49].
Linseman et al. had also found that mitochondria play a
key role in cell apoptosis because members of the Bcl-2
family proteins can interact with the mitochondrial outer
membrane [50], and that Bcl-2 and Bax can directly influ-
ence the mitochondrial membrane permeability, caspases,
and apoptosis [51, 52]. Based on these literature assess-
ments, we examined expression levels of Bcl-2 and Bax
and found that they changed in an expected manner after
exposing cells to cinchonine at different time periods.
We conducted preliminary animal studies to explore
possible tumor suppression using cinchonine. Some inci-
sion enzyme of DNA will be active to make DNA frag-
mentation when cells undergo apoptosis. TUNEL is a
common method for detecting DNA fragmentation in
situ [34]. Cinchonine inhibited tumor growth as deter-
mined by tumor volume. TUNEL results demonstrated
that incision enzyme of DNA was fragmented when
treated with cinchonine, thereby confirming that cin-
chonine could induce apoptosis in nude mice.
In relations to the immune system, reports have shown
that the C-terminus (333–508) of TRAF6 binds to
CD40, and thus, TRAF6 could play a significant role in
immunology [53]. In this study, we chose the RING do-
main of TRAF6, because it is the binding domain for
Ubc13 and represents a potential therapeutic target for
cancers. Nevertheless, it is important to recognize that
cellular functions of Ubc13 are critical in the context of
innate immune responses. By employing methods for
targeted gene ablation in mice, Fukushima et al. demon-
strated that ablation of the gene encoding Ubc13 in
homozygous mice resulted in embryonic lethality. How-
ever, despite a reduced level of the Ubc13 protein, het-
erozygous mice have normal phenotypes and exhibit no
abnormalities in immune cell populations [54]. There-
fore, these reports suggest that a reduced level of the
Ubc13 protein does not appear to compromise functions
of the immune system.
Lastly, to ensure that cinchonine could indeed bind with
TRAF6 in cells, we designed and synthesized a new cinchon-
ine derivative containing a coumarin-derived fluorescent
Fig. 7 Cinchonine inhibited tumor growth and induced apoptosis in nude mice. a The growth ratio of the control group (2.839 ± 0.583) was
greater than experiment I (2.266 ± 0.467) and experiment II (1.324 ± 0.367 P < 0.05). b The control group, which was treated with no cinchonine,
showed nearly no TUNEL positive cells. In experimental group-I and group-II, showed more TUNEL positive cells when treated with cinchonine.
The result demonstrates that cinchonine can induce apoptosis and the quantity of apoptosis is dose-dependent
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probe. It is important to note that the 7-aminocoumarin
probe was specifically conjugated to the terminal olefin of
cinchonine because the resulting fluorophore should re-
main outside the RING domain based on the modeling.
Thus, such structural modification would not diminish
the ability of cinchonine to interact with TRAF6. Subse-
quent immunofluorescence staining distinctly verifies that
cinchonine could bind with TRAF6 in cells, and thus, it
supports our docking studies and further substantiates the
potential of TRAF6 serving as an antitumor target.
Conclusions
In summary, computational modeling predicted that cin-
chonine could complex with the RING domain of TRAF6,
leading to disruption of the binding with its natural ligand
the Ubc13 protein that is critical for initiating downstream
events of AKT and TAK1 activations. Immmunofluores-
cence staining validates such interaction in cells when using
modified cinchonine containing a coumarin-derived fluor-
escent probe. Subsequent both in vitro and in vivo experi-
ments distinctly demonstrate that cinchonine could induce
apoptosis and reduce proliferation of cancer cells; and that
the mode of action is blocking the AKT and TAK1 activa-
tions though interfering the formation of the TRAF6-
Ubc13 complex. The RING domain of TRFA6 can be
regarded as a potentially useful antitumor target and efforts
are underway to further investigate such potential.
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